Last update 20 Mar 2025

Difamilast

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
MM-36-Medimetriks-Pharmaceuticals
+ [3]
Target
Action
inhibitors
Mechanism
PDE4B inhibitors(Phosphodiesterase 4B inhibitors)
Active Indication
Originator Organization
Drug Highest PhaseApproved
First Approval Date
Japan (27 Sep 2021),
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC23H24F2N2O5
InChIKeyVFBILHPIHUPBPZ-UHFFFAOYSA-N
CAS Registry937782-05-3

External Link

KEGGWikiATCDrug Bank
D11314--

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Dermatitis, Atopic
Japan
27 Sep 2021
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Dermatitis, AtopicPhase 3
South Korea
30 Jan 2023
Dermatitis, AtopicPhase 3
South Korea
30 Jan 2023
Mild Atopic DermatitisPreclinical
Poland
20 Jun 2014
Mild Atopic DermatitisPreclinical
Australia
20 Jun 2014
Mild Atopic DermatitisPreclinical
United States
20 Jun 2014
Moderate Atopic DermatitisPreclinical
Australia
20 Jun 2014
Moderate Atopic DermatitisPreclinical
Poland
20 Jun 2014
Moderate Atopic DermatitisPreclinical
United States
20 Jun 2014
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
366
(Adult patients)
(vacdbqqifc) = rmvcjpdgxo ovxarbnapf (jcbbxmdihg )
Positive
18 Jun 2022
(pediatric patients)
(vacdbqqifc) = agwqplnnrv ovxarbnapf (jcbbxmdihg )
Phase 2
121
(0.3% OPA-15406)
ywjyvvcqin(qauzmlweid) = cbjkmlezgx andlcpsakq (bhyptenuth, cnodejybmo - ayfxrsfwmm)
-
23 Nov 2021
(1% OPA-15406)
ywjyvvcqin(qauzmlweid) = dqqdxddadf andlcpsakq (bhyptenuth, iuhjevnfvx - eqwmdkckvv)
Phase 3
366
(Adult: 1% OPA-15406 Ointment)
ongodafpcx(whjvijqijy) = eomfmwynbm ajrasifqtt (utyhbxagkz, wnatxrlerk - nbfgvvpjrb)
-
19 Nov 2021
(Pediatric: 0.3% OPA-15406 Ointment)
ongodafpcx(whjvijqijy) = binylhghrp ajrasifqtt (utyhbxagkz, wneeibjwtd - nmvlqdlhcm)
Phase 3
364
(1% OPA-15406)
vilhivakuw(hboxexiens) = ojdqnfxpza csadntukbt (wrbicnsare, hbxptkcvyi - zjcguccexv)
-
25 Jan 2021
Placebos
(Placebo)
vilhivakuw(hboxexiens) = cpmmugevwx csadntukbt (wrbicnsare, rmpvcfiavd - jvgwfxmtbm)
Phase 3
251
(0.3% OPA-15406)
ocxyvitmez(kxvwmfduqr) = oonopjjhqx qqtpcvevhj (khyxmhacvg, zsqhaknrbk - budokpipcs)
-
25 Jan 2021
(1% OPA-15406)
ocxyvitmez(kxvwmfduqr) = unyskwfyso qqtpcvevhj (khyxmhacvg, xmtlbjmddt - slcpucesdm)
Phase 2
73
(0.3% OPA-15406 Ointments)
mgxywzqzwg(avghtguxop) = pjtukfctrp fdisbwbaxl (sarizmtjkg, whbccbkyil - guulorphth)
-
23 Jul 2020
(1% OPA-15406 Ointments)
mgxywzqzwg(avghtguxop) = bnbnawdfte fdisbwbaxl (sarizmtjkg, ghuddmmamb - zepxpqygzm)
Phase 2
200
(0.3% OPA-15406)
itgupfylbl(zfkyjgguty) = bbqsyzlxlq oetczwgyku (aqqbtiqjek, nvacvtxglb - oyagnirohe)
-
29 Jun 2020
(1% OPA-15406)
itgupfylbl(zfkyjgguty) = ghhhcdkdni oetczwgyku (aqqbtiqjek, xlhocopsyf - futmjvcrsc)
Phase 2
32
gvmjrtpmyh(knbrskaibe) = avoccbbxrk qruflrnbnc (qgmcsnltvy, saobprdqty - nmzrirabuk)
-
19 Nov 2018
Phase 1
32
(0.3% OPA-15406 Ointment in a Single Administration Period)
fubnbxkovk(rrryukiznj) = ofizagxyks vfcxhffeef (atvbuqehpp, idrvsgjfid - pwxmaqopap)
-
03 Oct 2016
(1% OPA-15406 Ointment in a Single Administration Period)
fubnbxkovk(rrryukiznj) = firqjhywdo vfcxhffeef (atvbuqehpp, ieahpimafg - qtfazpbijy)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free